Gregory Conn
Chief Tech/Sci/R&D Officer bei PDS BIOTECHNOLOGY CORPORATION
Vermögen: 457 558 $ am 31.03.2024
Profil
Gregory L.
Conn is the founder of PDS Operating Corp.
He is currently the Chief Scientific Officer at PDS Biotechnology Corp.
He previously worked as the Director of the Process Development Department at Covance Biotechnology Services, Inc. from 1998 to 2000.
Dr. Conn holds a graduate and doctorate degree from Albert Einstein College of Medicine, Inc.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
PDS BIOTECHNOLOGY CORP.
0,37% | 05.01.2023 | 115 545 ( 0,37% ) | 457 558 $ | 31.03.2024 |
Aktive Positionen von Gregory Conn
| Unternehmen | Position | Beginn |
|---|---|---|
| PDS BIOTECHNOLOGY CORPORATION | Chief Tech/Sci/R&D Officer | 15.03.2019 |
Ehemalige bekannte Positionen von Gregory Conn
| Unternehmen | Position | Ende |
|---|---|---|
Covance Biotechnology Services, Inc.
 Covance Biotechnology Services, Inc. Pharmaceuticals: MajorHealth Technology Covance Biotechnology Services, Inc. develops pharmaceutical products. The company offers two microbiology laboratories, one for mycoplasma analysis, and a second for molecular biology. It provides services to biomolecules, including recombinant proteins, monoclonal antibodies, vaccines, blood products, and gene therapy products. The company was founded by Richard J. Hawkins, V. Bryan Lawlis, and John A. Scarlett in 1995 and is headquartered in Princeton, NJ. | Corporate Officer/Principal | 01.01.2000 |
PDS Operating Corp.
 PDS Operating Corp. BiotechnologyHealth Technology PDS Operating Corp. operates as a biopharmaceutical company. It develops immunotherapies for cancer and infectious disease. The firm’s versamune is capable of potent activation of immune cells without the side effects of traditional vaccines, efficiently delivering disease related antigen targets to the immune system and promoting antigen processing to present antigen appropriately to generate both strong prophylactic and therapeutic immune responses to disease. The company was founded by Frank K. Bedu-Addo and Gregory L. Conn and is headquartered in Princeton, NJ. | Founder | - |
Ausbildung von Gregory Conn
| Albert Einstein College of Medicine, Inc. | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| PDS BIOTECHNOLOGY CORPORATION | Health Technology |
| Private Unternehmen | 2 |
|---|---|
PDS Operating Corp.
PDS Operating Corp. BiotechnologyHealth Technology PDS Operating Corp. operates as a biopharmaceutical company. It develops immunotherapies for cancer and infectious disease. The firm’s versamune is capable of potent activation of immune cells without the side effects of traditional vaccines, efficiently delivering disease related antigen targets to the immune system and promoting antigen processing to present antigen appropriately to generate both strong prophylactic and therapeutic immune responses to disease. The company was founded by Frank K. Bedu-Addo and Gregory L. Conn and is headquartered in Princeton, NJ. | Health Technology |
Covance Biotechnology Services, Inc.
Covance Biotechnology Services, Inc. Pharmaceuticals: MajorHealth Technology Covance Biotechnology Services, Inc. develops pharmaceutical products. The company offers two microbiology laboratories, one for mycoplasma analysis, and a second for molecular biology. It provides services to biomolecules, including recombinant proteins, monoclonal antibodies, vaccines, blood products, and gene therapy products. The company was founded by Richard J. Hawkins, V. Bryan Lawlis, and John A. Scarlett in 1995 and is headquartered in Princeton, NJ. | Health Technology |
